Nimenrix®
(Meningococcal group ACW₁₃₅Y conjugate vaccine)

What is Nimenrix and what is it used for?

Nimenrix is a conjugate vaccine that helps to provide protection against invasive disease caused by the bacteria Neisseria meningitidis types A, C, W-135 and Y. Invasive disease occurs when there is systemic spread of bacterium throughout the body causing serious infections such as septicaemia (blood infection) and meningitis (infection of the membranes around the brain and spinal cord).

Nimenrix may be given to adults, adolescents, children and infants over the age of 6 weeks.

Nimenrix will only protect against infections caused by the bacteria Neisseria meningitidis types A, C, W-135 and Y. As with all vaccines, Nimenrix may not protect everyone who is fully vaccinated.
 

When should the vaccine be administered?

Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks and should be used in accordance with official available recommendations.

The medicine can only be obtained with a prescription.
 

Reference Information

The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in Amsterdam, the Netherlands. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See what guidance they offer about Nimenrix.

Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Nimenrix please follow these links:


Great Britain
Nimenrix (Meningococcal group ACW₁₃₅Y conjugate vaccine)

Northern Ireland
Nimenrix (Meningococcal group ACW₁₃₅Y conjugate vaccine)

 

View the national immunisation schedule

 

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

  PP-NIM-GBR-0302 / October 2021